$Bionomics (BNOX.US)$ Bionomics (Nasdaq: BNOX), a clinical-s...

Bionomics (Nasdaq: BNOX), a clinical-stage biotechnology company, has announced a corporate update and discussion of end-of-Phase 2 (EoP2) meeting outcomes with the FDA regarding the advancement of BNC210 for post-traumatic stress disorder (PTSD) treatment into Phase 3. The update will be provided on July 31, 2024, at 8:00 am ET via a conference call and webcast presentation.

Interested parties can access the call using the provided toll-free and international numbers, along with the conference ID. A webcast link is also available, and a replay will be posted on Bionomics' website Events page under the Investors section after the presentation.